Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Common Equity (2019 - 2025)

Eton Pharmaceuticals' Common Equity history spans 7 years, with the latest figure at $23.1 million for Q3 2025.

  • For Q3 2025, Common Equity rose 44.71% year-over-year to $23.1 million; the TTM value through Sep 2025 reached $23.1 million, up 44.71%, while the annual FY2024 figure was $24.4 million, 57.83% up from the prior year.
  • Common Equity for Q3 2025 was $23.1 million at Eton Pharmaceuticals, down from $24.0 million in the prior quarter.
  • Across five years, Common Equity topped out at $24.4 million in Q1 2025 and bottomed at $11.2 million in Q3 2022.
  • The 5-year median for Common Equity is $16.0 million (2024), against an average of $17.2 million.
  • The largest annual shift saw Common Equity surged 1028.24% in 2021 before it plummeted 37.91% in 2022.
  • A 5-year view of Common Equity shows it stood at $17.6 million in 2021, then decreased by 25.82% to $13.1 million in 2022, then grew by 18.34% to $15.5 million in 2023, then skyrocketed by 57.83% to $24.4 million in 2024, then dropped by 5.33% to $23.1 million in 2025.
  • Per Business Quant, the three most recent readings for ETON's Common Equity are $23.1 million (Q3 2025), $24.0 million (Q2 2025), and $24.4 million (Q1 2025).